IN8bio (INAB) R&D Day 2026 summary

Pipeline overview and program updates

• Advancing a pipeline of gamma-delta T cell engagers (INB-619) for autoimmune and oncology, and drug-resistant immunotherapy platforms (INB-200/400) for glioblastoma, with multiple clinical and preclinical milestones anticipated in 2026.

• INB-619 targets CD19, activates both Vδ1 and Vδ2 gamma-delta T cell compartments, and is in IND-enabling studies, with initial mouse model data expected in 2026.

• INB-100 (DeltEx Allo γδ T cells) is in clinical development for AML; INB-200 (autologous) and INB-400 (allogeneic) are being evaluated in GBM with ongoing phase I/II trials and FDA guidance expected in 2026.

• Pipeline includes both autologous and allogeneic cell therapy approaches, with plans to expand allogeneic use and off-the-shelf availability.

Clinical trial data and development milestones

• INB-200/400 trials in newly diagnosed GBM show median progression-free survival of 13 months and overall survival of 17.2 months, both exceeding historical controls.

• INB-619 demonstrates potent, selective B cell depletion without CD3-driven toxicity, expanding both Vδ1 and Vδ2 γδ T cell subtypes and avoiding CRS.

• Repeat dosing of gamma-delta T cells in GBM patients correlates with sustained peripheral immune cell levels and improved survival, with no major toxicities, CRS, or ICANS observed.

• Single-cell and AI-driven tumor microenvironment analysis shows increased immune infiltration and reduced tumor proliferation post-treatment.

• Data from INB-200/400 to be updated at ASCO 2026, with peer-reviewed publication and further regulatory discussions planned.

R&D strategy and innovation priorities

• Focus on leveraging unique biology of gamma-delta T cells for autoimmune reset and solid tumor eradication.

• In-house development of a trispecific T cell engager platform with expansion domains to overcome previous limitations and enable safer, more targeted therapies.

• Investment in AI-powered tumor mapping and single-cell spatial analysis to guide future combination and intensification strategies.

• Emphasis on efficient capital deployment and rapid milestone achievement.